UPDATE: At the June 26, 2024 board meeting, members voted to pause the affordability reviews for 2024 so the board can review, assess and possibly improve the criteria and methods used to assess and select drugs for potential affordability reviews in 2025, using a refreshed data set. Listen to the board discussion and view the meeting video at minute
00:08:46.
PAUSED for 2024: board calendar for affordability review of insulin, prescription drugs
| Board meeting month and date | Drugs
| Deadline for written materials,
specific to drugs under review | Each affordability review will have the following agenda for each drug |
|---|
January 26, 2024 Completed
| Insulin:
Tresiba
Tresiba FlexTouch
Humulin R U-500 KwikPen | - | - |
May 15, 2024
Completed
|
Ozempic
Trulicity | May 5, 2024 | - Staff presentation
- Public comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers |
| June 26, 2024 | Shingrix
Ocrevus
Board voted June 26, 2024 to pause affordability reviews for 2024 and start again in January 2025
| June 16, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers |
| July 24, 2024 | Entyvio
Inflectra: board voted on 5/15/2024 to remove Inflectra from the review list | July 14, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers
|
| August 21, 2024 | Cosentyx
Skyrizi: board voted on 5/15/2024 to remove Skyrizi from the review list
| August 11, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers |
September 18, 2024
| Tremfya
Vyvanse
| September 8, 2024 | - Staff presentation
- Public Comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers |
October 16, 2024
| Genvoya
Triumeq
| October 6, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers
* General Public
* Manufacturers
* Carriers and providers
|
November 20, 2024
| |
| - Final review of drugs and approval of Legislative recommendations
|